Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PXD101 + cisplatin + doxorubicin + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- Valerio Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of belinostat (PXD101), cisplatin, doxorubicin, and cyclophosphamide. Belinostat is a histone deacetylase (HDAC) inhibitor that induces transformed cell differentiation, cell cycle arrest, and apoptosis by affecting chromatin structure and gene expression. It is approved for the treatment of peripheral T-cell lymphoma and has been studied in combination with other chemotherapeutic agents for various solid tumors and hematological malignancies[3][4]. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks leading to apoptosis. Doxorubicin is an anthracycline antibiotic that intercalates DNA strands and inhibits topoisomerase II activity. Cyclophosphamide is an alkylating agent used in the treatment of various cancers; it works by slowing or stopping the growth of cancer cells through DNA crosslinking[6][8][10]. This multi-agent regimen aims to leverage synergistic antitumor effects from different mechanisms.
- Other names
- belinostatPXD-101PXD101PXD 101Beleodaqcisplatindoxorubicincyclophosphamide
02
Targets
DNAHDAC (HDAC family)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on PXD101 + cisplatin + doxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PXD101 + cisplatin + doxorubicin + cyclophosphamide.